Autopsy report · NCT02357732

Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib

“PI decided not to proceed”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

University of Pittsburgh

Sponsor type

University, hospital or other

Conditions

Metastatic Melanoma

Interventions

Nivolumab; Trametinib; Dabrafenib

Participants

0

Trials that died the same way

• Pilot Study Investigating the Use of the ReBuilder to Treat Chemotherapy Induced Peripheral Neuropathy in Patients With Breast Cancer
  “PI decided no longer to pursue” (85% match in meaning)
• Pre-post Spinal Popliteal Block
  “Retrospective study that the PI decided not to proceed with” (78% match in meaning)
• Cross-sectional Study on a Given Day Within the Paris Saint-Joseph Hospital Group
  “The PI decided it.” (76% match in meaning)
• Subacromial Injection With Corticosteroid Versus Nonsteroidal Anti-inflammatory Drugs (NSAID) in Shoulder Impingement Syndrome
  “PI didn't have time to finish approval process” (73% match in meaning)
• Breast Arterial Calcifications as an Imaging Biomarker of Cardiovascular Risk
  “PI ceased activity” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.